From ancient leech to direct thrombin inhibitors and beyond: New from old
Review published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022)
Abstract
Medicinal leeches have been used in health care since before written history, with widely varying popularity over the centuries. Nowadays, medicinal leech therapy is mainly used in plastic and reconstructive microsurgery, with new interesting potential therapeutic applications in many other diseases. The leech's best-known salivary product, hirudin - one of the most powerful natural anticoagulants - was the only remedy to prevent blood clotting until the discovery of heparin. Starting from hirudin, pharmacological research succeeded in developing new anticoagulants, which represent a cornerstone of prevention and treatment of thromboembolic disease. While we are perhaps on the threshold of a new era of anticoagulation, with the development of FXI and XII inhibitors and direct reversible covalent thrombin inhibitors, which promise to achieve effective anticoagulation without bleeding risk. This review retraces the intriguing journey of these drugs in cardiovascular disease, highlighting the fil rouge that links the ancient leech to the current and oncoming antithrombotic therapy. We think that knowledge of the past is key to understanding and appreciating the present and to seize future opportunities.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This review traces the historical line from leech-derived hirudin to modern direct thrombin inhibitors and emerging FXI/XII inhibitors and reversible covalent thrombin inhibitors, linking ancient leech therapy to contemporary antithrombotic drug development.
Why This Matters for Hirudotherapy
This review traces the historical and pharmacological trajectory from medicinal leech therapy and its salivary anticoagulant hirudin to the development of modern direct thrombin inhibitors and emerging antithrombotic agents such as FXI/XII inhibitors and reversible covalent thrombin inhibitors. The review positions leech-derived hirudin as the foundational molecule that catalyzed an entire class of anticoagulant drugs, and notes current clinical use of medicinal leeches in plastic and reconstructive microsurgery and potential expansion into other therapeutic areas. As a review, it provides historical and conceptual synthesis rather than original experimental or clinical data, and its primary emphasis is on pharmaceutical anticoagulant development rather than on characterizing the broader leech salivary secretome or reporting hirudotherapy outcomes.
Citation
Reference (Vancouver style)
Montinari MR, Minelli S. From ancient leech to direct thrombin inhibitors and beyond: New from old. Biomed Pharmacother. 2022;149:112878. doi:10.1016/j.biopha.2022.112878. PMID: 35364378
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026